Sharma Gunjan, Sultana Ashrafi, Abdullah K M, Pothuraju Ramesh, Nasser Mohd Wasim, Batra Surinder Kumar, Siddiqui Jawed Akhtar
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Semin Cell Dev Biol. 2024 Feb 15;154(Pt C):275-285. doi: 10.1016/j.semcdb.2022.11.002. Epub 2022 Nov 12.
Bone remodeling is a continuous and dynamic process of bone formation and resorption to maintain its integrity and homeostasis. Bone marrow is a source of various cell lineages, including osteoblasts and osteoclasts, which are involved in bone formation and resorption, respectively, to maintain bone homeostasis. Epigenetics is one of the elementary regulations governing the physiology of bone remodeling. Epigenetic modifications, mainly DNA methylation, histone modifications, and non-coding RNAs, regulate stable transcriptional programs without causing specific heritable alterations. DNA methylation in CpG-rich promoters of the gene is primarily correlated with gene silencing, and histone modifications are associated with transcriptional activation/inactivation. However, non-coding RNAs regulate the metastatic potential of cancer cells to metastasize at secondary sites. Deregulated or altered epigenetic modifications are often seen in many cancers and interwound with bone-specific tropism and cancer metastasis. Histone acetyltransferases, histone deacetylase, and DNA methyltransferases are promising targets in epigenetically altered cancer. High throughput epigenome mapping and targeting specific epigenetics modifiers will be helpful in the development of personalized epi-drugs for advanced and bone metastasis cancer patients. This review aims to discuss and gather more knowledge about different epigenetic modifications in bone remodeling and metastasis. Further, it provides new approaches for targeting epigenetic changes and therapy research.
骨重塑是一个持续且动态的骨形成与吸收过程,以维持骨骼的完整性和内环境稳定。骨髓是多种细胞谱系的来源,包括成骨细胞和破骨细胞,它们分别参与骨形成和骨吸收,以维持骨内环境稳定。表观遗传学是调控骨重塑生理学的基本机制之一。表观遗传修饰,主要包括DNA甲基化、组蛋白修饰和非编码RNA,可调节稳定的转录程序而不引起特定的可遗传改变。基因富含CpG的启动子区域的DNA甲基化主要与基因沉默相关,而组蛋白修饰则与转录激活/失活有关。然而,非编码RNA可调节癌细胞转移至继发部位的转移潜能。在许多癌症中常可见到失调或改变的表观遗传修饰,且与骨特异性趋向性和癌症转移相互交织。组蛋白乙酰转移酶、组蛋白去乙酰化酶和DNA甲基转移酶是表观遗传改变的癌症中有前景的靶点。高通量表观基因组图谱绘制和靶向特定的表观遗传修饰剂将有助于为晚期和骨转移癌症患者开发个性化的表观遗传药物。本综述旨在讨论并收集更多关于骨重塑和转移中不同表观遗传修饰的知识。此外,它为靶向表观遗传变化和治疗研究提供了新方法。